**Meet the editor**

Nima Rezaei, born in 1976, received his Medical Degree from Tehran University of Medical Sciences in 2002. He received his M.Sc. and Ph.D. degrees in the field of Clinical Immunology and Genetic Medicine from the University of Sheffield in 2007 and 2009, respectively, as well as a short-term fellowship, awarded by the ESID, in the Paediatric Immunology and BMT Unit of the Newcastle

General Hospital. He is already the Chief Executive Director of the Children's Medical Center Hospital, the Pediatrics Center of Excellence in Iran as well as the Deputy President of the Research Center for Immunodeficiencies. He has presented more than 200 lectures/posters in congresses and has published more than 250 articles in international scientific journals during last decade.

### Contents

#### **Preface XI**

	- **Part 2 Advances in Classical Hodgkin's Lymphoma Biology: New Prognostic Factors and Outcome Prediction Using Gene Expression Signatures 27**
	- **Part 3 Epidemiology of Hodgkin's Lymphoma 47**
	- **Part 4 Hodgkin's Lymphoma: From Tumor Microenvironment to Immunotherapeutic Approach – Body's Own Power Protection Challenges 61**
	- **Part 5 Treatment of Early Stage Hodgkin's Lymphoma 111**

X Contents


Chapter 11 **Survivorship in Hodgkin Lymphoma 255**  Matthew A. Lunning and Matthew J. Matasar

### Preface

Hodgkin's lymphoma, previously known as Hodgkin's disease, is recognized as B cell derived cancer of lymphatic system. Although the disease had been described about 180 years ago, its exact causes and pathophysiology still remains unknown. However, there have been some progresses in identifying some genetic and environmental risk factors in development of lymphoma. Considering recent advances in treatment of patients with lymphoma during last two decades, the disease is considered as a curable disease, but it is still a controversial subject.

The current book consists of 11 chapters. Recent insights into the biology of Hodgkin's lymphoma, including historical aspects, epidemiology, pathophysiology, genetic defects, and prognostic indicators are explained in the chapters 1-3. Chapter 4 is a translational chapter from tumor microenvironment to immunotherapeutic approach, followed by the chapters 5-9, explaining treatment of early stage, advanced, and refractory Hodgkin's lymphoma as well as MALT lymphoma, respectively. The chapter 10 briefly explains some adverse effects of chemotherapy and radiotherapy in the affected patients, while the final chapter is focused on survivorship in Hodgkin's lymphoma. These chapters are intended to help physicians as well as medical students to learn and understand the pathophysiology of Hodgkin's lymphoma as well as practical approach to diagnosis and management in clinical practice.

The book is the result of valuable contribution of 20 scientists in this field and I would like to acknowledge the expertise of all contributors, for generously giving their time and considerable effort in preparing their respective chapters. I hope the book will be welcomed by the physicians, who wish to learn more about Hodgkin's lymphoma.

> **Nima Rezaei, MD, PhD** Research Center for Immunodeficiencies, Children's Medical Center, Tehran University of Medical Sciences, Tehran, Iran
